UNC0379CAS# 1620401-82-2 |
- AZ505 ditrifluoroacetate
Catalog No.:BCC4265
CAS No.:1035227-44-1
- UNC0638
Catalog No.:BCC1135
CAS No.:1255580-76-7
- EPZ005687
Catalog No.:BCC2219
CAS No.:1396772-26-1
- UNC0379
Catalog No.:BCC8055
CAS No.:1620401-82-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1620401-82-2 | SDF | Download SDF |
PubChem ID | 78357767 | Appearance | Powder |
Formula | C23H35N5O2 | M.Wt | 413.56 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 50 mg/mL (120.90 mM; Need ultrasonic) | ||
Chemical Name | 6,7-dimethoxy-2-pyrrolidin-1-yl-N-(5-pyrrolidin-1-ylpentyl)quinazolin-4-amine | ||
SMILES | COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCCC3)NCCCCCN4CCCC4)OC | ||
Standard InChIKey | WEXCGGWTIDNVNT-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C23H35N5O2/c1-29-20-16-18-19(17-21(20)30-2)25-23(28-14-8-9-15-28)26-22(18)24-10-4-3-5-11-27-12-6-7-13-27/h16-17H,3-15H2,1-2H3,(H,24,25,26) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
UNC0379 Dilution Calculator
UNC0379 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.418 mL | 12.0901 mL | 24.1803 mL | 48.3606 mL | 60.4507 mL |
5 mM | 0.4836 mL | 2.418 mL | 4.8361 mL | 9.6721 mL | 12.0901 mL |
10 mM | 0.2418 mL | 1.209 mL | 2.418 mL | 4.8361 mL | 6.0451 mL |
50 mM | 0.0484 mL | 0.2418 mL | 0.4836 mL | 0.9672 mL | 1.209 mL |
100 mM | 0.0242 mL | 0.1209 mL | 0.2418 mL | 0.4836 mL | 0.6045 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
UNC0379 is a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8 with IC50 of 7.3±1.0 uM; selective over 15 other methyltransferases.
- Rofecoxib
Catalog No.:BCC4437
CAS No.:162011-90-7
- Bromosporine
Catalog No.:BCC2226
CAS No.:1619994-69-2
- GSK2801
Catalog No.:BCC6498
CAS No.:1619994-68-1
- LY2857785
Catalog No.:BCC8050
CAS No.:1619903-54-6
- Catechin pentaacetate
Catalog No.:BCN1718
CAS No.:16198-01-9
- Esomeprazole Magnesium
Catalog No.:BCC5007
CAS No.:161973-10-0
- Prehelminthosporol
Catalog No.:BCN7447
CAS No.:1619-13-2
- Segetalin A
Catalog No.:BCC9246
CAS No.:161875-97-4
- Talampanel(LY300164)
Catalog No.:BCC6378
CAS No.:161832-65-1
- Amprenavir (agenerase)
Catalog No.:BCC3619
CAS No.:161814-49-9
- Benzamil
Catalog No.:BCC7674
CAS No.:161804-20-2
- Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate
Catalog No.:BCC8966
CAS No.:161798-02-3
- L-371,257
Catalog No.:BCC7353
CAS No.:162042-44-6
- SC 58125
Catalog No.:BCC5948
CAS No.:162054-19-5
- Myriceric acid C
Catalog No.:BCN1719
CAS No.:162059-94-1
- Dimesna
Catalog No.:BCC1095
CAS No.:16208-51-8
- 4',4'''-Di-O-methylisochamaejasmin
Catalog No.:BCN6849
CAS No.:1620921-68-7
- SynaptoRedTM C2
Catalog No.:BCC8012
CAS No.:162112-35-8
- RWJ 50271
Catalog No.:BCC7894
CAS No.:162112-37-0
- Flunitrazepam
Catalog No.:BCC6107
CAS No.:1622-62-4
- Melperone hydrochloride
Catalog No.:BCC7385
CAS No.:1622-79-3
- 5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine 2',3'-diacetate
Catalog No.:BCN1544
CAS No.:162204-20-8
- Dorsmanin A
Catalog No.:BCN4088
CAS No.:162229-27-8
- CI 1020
Catalog No.:BCC7523
CAS No.:162256-50-0
Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.[Pubmed:28073004]
Cancer Cell. 2017 Jan 9;31(1):50-63.
Given the paucity of druggable mutations in high-risk neuroblastoma (NB), we undertook chromatin-focused small interfering RNA and chemical screens to uncover epigenetic regulators critical for the differentiation block in high-risk NB. High-content Opera imaging identified 53 genes whose loss of expression led to a decrease in NB cell proliferation and 16 also induced differentiation. From these, the secondary chemical screen identified SETD8, the H4(K20me1) methyltransferase, as a druggable NB target. Functional studies revealed that SETD8 ablation rescued the pro-apoptotic and cell-cycle arrest functions of p53 by decreasing p53(K382me1), leading to activation of the p53 canonical pathway. In pre-clinical xenograft NB models, genetic or pharmacological (UNC0379) SETD8 inhibition conferred a significant survival advantage, providing evidence for SETD8 as a therapeutic target in NB.
Structure-activity relationship studies of SETD8 inhibitors.[Pubmed:25554733]
Medchemcomm. 2014 Dec;5(12):1892-1898.
SETD8 (also known as SET8, PR-SET7, or KMT5A (lysine methyltransferase 5A)) is the only known lysine methyltransferase that catalyzes monomethylation of histone H4 lysine 20 (H4K20). In addition to H4K20, SETD8 monomethylates non-histone substrates such as the tumor suppressor p53 and proliferating cell nuclear antigen (PCNA). Because of its role in regulating diverse biological processes, SETD8 has been pursued as a potential therapeutic target. We recently reported the first substrate-competitive SETD8 inhibitor, UNC0379 (1), which is selective for SETD8 over 15 other methyltransferases. We characterized this inhibitor in a battery of biochemical and biophysical assays. Here we describe our comprehensive structure-activity relationship (SAR) studies of this chemical series. In addition to 2- and 4-substituents, we extensively explored 6- and 7-substituents of the quinazoline scaffold. These SAR studies led to the discovery of several new compounds, which displayed similar potencies as compound 1, and interesting SAR trends.
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.[Pubmed:25032507]
J Med Chem. 2014 Aug 14;57(15):6822-33.
The lysine methyltransferase SETD8 is the only known methyltransferase that catalyzes monomethylation of histone H4 lysine 20 (H4K20). Monomethylation of H4K20 has been implicated in regulating diverse biological processes including the DNA damage response. In addition to H4K20, SETD8 monomethylates non-histone substrates including proliferating cell nuclear antigen (PCNA) and promotes carcinogenesis by deregulating PCNA expression. However, selective inhibitors of SETD8 are scarce. The only known selective inhibitor of SETD8 to date is nahuoic acid A, a marine natural product, which is competitive with the cofactor. Here, we report the discovery of the first substrate-competitive inhibitor of SETD8, UNC0379 (1). This small-molecule inhibitor is active in multiple biochemical assays. Its affinity to SETD8 was confirmed by ITC (isothermal titration calorimetry) and SPR (surface plasmon resonance) studies. Importantly, compound 1 is selective for SETD8 over 15 other methyltransferases. We also describe structure-activity relationships (SAR) of this series.